Western blot - Calnexin - ER membrane marker antibody - ER Marker (ab10286)

Predicted band size : 67 kDa


Western blot probed with ab10286 at 1/1000. Lane 1 – calnexin deficient human NKR T-lymphoblastoid leukemia cell lines. Lane 2 - human CEM T-lymphoblastoid leukemia cell lines.

Western blot - Calnexin antibody - ER Marker (ab10286)

Anti-Calnexin - ER membrane marker antibody - ER Marker (ab10286) at 1/1000 dilution + MCF7 cells

Secondary
Goat anti rabbit at 1/10000 dilution

Predicted band size : 67 kDa

Western blot - Calnexin - ER membrane marker antibody - ER Marker (ab10286)

All lanes : Anti-Calnexin - ER membrane marker antibody - ER Marker (ab10286) at 1/4000 dilution

Lane 1 : HeLa (Total cell lysate)
Lane 2 : HeLa (Membrane fraction)
Lane 3 : HeLa (Cytoplasmic fraction)
Lane 4 : MDA-MB231 (Total cell lysate)
Lane 5 : MDA-MB231 (Membrane fraction)
Lane 6 : MDA-MB231 (Cytoplasmic fraction)

Secondary
HRP conjugated donkey anti-rabbit
developed using the ECL technique

Performed under reducing conditions.

Predicted band size : 67 kDa
Observed band size : 67 kDa


Exposure time : 5 minutes

This image is courtesy of an Abreview submitted by Dr Neil Taylor

Immunocytochemistry/ Immunofluorescence - Calnexin - ER membrane marker antibody - ER Marker (ab10286)

Paraformaldehyde fixed HeLa cells stained with ab10286. For further details please refer to the customer Abreview.

Image taken from an Abreview submitted by Dr Neil Taylor

Immunocytochemistry/ Immunofluorescence - Calnexin - ER membrane marker antibody - ER Marker (ab10286)

ab10286 staining Calnexin in Pig retinal pigment epithelial cells by ICC/IF (Immunocytochemistry/immunoflurescence). Cells were fixed with paraformaldehyde, permeabilized with 0.5% TX-100 and blocked with 5% serum for 20 minutes at 25ºC. Samples were incubated with primary antibody (1/500 in 0.1% TX100; 1% goat serum; 1XPBS) for 16 hours at 4ºC. An Alexa Fluor^® 488-conjugated Goat polyclonal to rabbit IgG, dilution 1/500, was used as secondary antibody.

This image is courtesy of an Abreview submitted by Dr. Vladimir Milenkovic